Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Sorrento and Yuhan create immuno-oncology joint venture, ImmuneOncia

Executive Summary

Sorrento Therapeutics Inc. and Yuhan Corp. have come together to form a new cancer-focused joint venture called ImmuneOncia Therapeutics LLC. The venture will be 51% owned by Yuhan, located in Yuhan's research center, and head by Yuhan CSO Dr. Su Youn Nam.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Joint Venture
    • Intra-Biotech Deal

Related Companies